Bayer will pay up to $600 for the 59.2% stake in engineered-cell therapy developer BlueRock Therapeutics it does now own, following a $225m round in 2016.
Pharmaceutical and chemical producer Bayer acquired US-based stem cell treatment developer and portfolio company BlueRock Therapeutics yesterday in a deal that could value it at up to $1bn.
BlueRock is looking to engineer stem cells using its proprietary induced stem cell (iPSC) platform in order to treat neurological, immunological and heart diseases. Its drug candidates include a potential Parkinson’s disease treatment it aims to advance into the clinic by the end of 2019.
The company was founded by venture capital…
